{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:34:25Z","timestamp":1790213665033,"version":"4.1.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Echinocandins are recommended for the treatment of suspected or confirmed invasive candidiasis (IC) in adults. Less is known about the use of echinocandins for the management of IC in children. The aim of this study was to investigate the overall efficacy and safety of echinocandin class in neonatal and pediatric patients with IC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>PubMed, Cochrane Central, Scopus and Clinical trial registries were searched up to July 27, 2017. Eligible studies were randomized controlled trials that evaluated the efficacy and safety of any echinocandin versus agents of other antifungal classes for the treatment of IC in pediatric patients. The primary outcome was treatment success with resolution of symptoms and signs, and absence of IC. In the meta-analysis a random effects model was used, and the odds ratio (OR) and 95% confidence intervals (CIs) were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Four randomized clinical trials (324 patients), 2 confirmed IC (micafungin vs. liposomal amphotericin B (L-AmB) and caspofungin vs. L-AmB) and 2 empirical therapy trials (caspofungin vs. deoxycholate amphotericin B and caspofungin vs. L-AmB) were included. There was no significant difference between echinocandins and comparator in terms of treatment success (OR = 1.61, 95% CI: 0.74\u20133.50) and incidence of treatment-related adverse events (OR = 0.70, 95% CI: 0.39\u20131.26). However, fewer children treated with echinocandins discontinued treatment because of adverse events than amphotericin B formulations (OR = 0.26, 95% CI: 0.08\u20130.82,<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In the treatment of IC in children, echinocandins show non-inferior efficacy compared with amphotericin B formulations with fewer discontinuations than in comparator arm.<\/jats:p><\/jats:sec>","DOI":"10.1097\/inf.0000000000002032","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T03:16:41Z","timestamp":1522293401000},"page":"42-49","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children"],"prefix":"10.1097","volume":"38","author":[{"given":"Magdalini","family":"Tsekoura","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences"},{"name":"Microbiology Department, Papanikolaou General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ioannidou","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences"},{"name":"Second Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, AHEPA General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi-Dorothea","family":"Pana","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences"},{"name":"Second Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, AHEPA General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Bettina","family":"Haidich","sequence":"additional","affiliation":[{"name":"Department of Hygiene and Epidemiology, Aristotle University School of Health Sciences, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Antachopoulos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kolios","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology, Faculty of Medicine, Democritus University of Thrace, Alexandroupolis, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Third Department of Paediatrics, Faculty of Medicine, Aristotle University School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/INF.0b013e3182737427","article-title":"Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.","volume":"31","author":"Steinbach","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/INF.0000000000000009","article-title":"Invasive Candidiasis in preterm neonates in China: a retrospective study from 11 NICUS during 2009-2011.","volume":"33","author":"Xia","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1542\/peds.2009-3412","article-title":"Neonatal candidiasis: epidemiology, risk factors, and clinical judgment.","volume":"126","author":"Benjamin","year":"2010","journal-title":"Pediatrics"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1542\/peds.2006-2931","article-title":"Antifungal therapy in children with invasive fungal infections: a systematic review.","volume":"119","author":"Blyth","year":"2007","journal-title":"Pediatrics"},{"issue":"suppl 1","key":"R6-20230928","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.earlhumdev.2011.01.017","article-title":"Invasive candidiasis in neonates and children.","volume":"87","author":"Roilides","year":"2011","journal-title":"Early Hum Dev"},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00134-007-0672-5","article-title":"Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.","volume":"33","author":"Filioti","year":"2007","journal-title":"Intensive Care Med"},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1542\/peds.2008-2055","article-title":"Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients.","volume":"123","author":"Blyth","year":"2009","journal-title":"Pediatrics"},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10096-004-1210-9","article-title":"Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates.","volume":"23","author":"Roilides","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/376906","article-title":"A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R11-20230928","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/mmy.39.1.55.66","article-title":"Fungal beta(1,3)-D-glucan synthesis.","volume":"39","author":"Douglas","year":"2001","journal-title":"Med Mycol"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2146\/ajhp050464.p1","article-title":"Echinocandins in the management of invasive fungal infections, part 1.","volume":"63","author":"Morris","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/2047-783X-16-4-159","article-title":"Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.","volume":"16","author":"Kofla","year":"2011","journal-title":"Eur J Med Res"},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed.","volume":"31","author":"Robinson","year":"2002","journal-title":"Int J Epidemiol"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/ejh.12641","article-title":"Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.","volume":"96","author":"Oyake","year":"2016","journal-title":"Eur J Haematol"},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial.","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/myc.12104","article-title":"Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.","volume":"57","author":"Cornely","year":"2014","journal-title":"Mycoses"},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2710.2012.01362.x","article-title":"Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.","volume":"37","author":"Shang","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1186\/cc10514","article-title":"Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.","volume":"15","author":"Kett","year":"2011","journal-title":"Crit Care"},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-2334-11-261","article-title":"Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.","volume":"11","author":"Reboli","year":"2011","journal-title":"BMC Infect Dis"},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1186\/cc8117","article-title":"Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.","volume":"13","author":"Dupont","year":"2009","journal-title":"Crit Care"},{"key":"R28-20230928","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).","volume":"110","author":"Caillot","year":"2007","journal-title":"Cancer"},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/AAC.50.1.143-147.2006","article-title":"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.","volume":"50","author":"Mattiuzzi","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2169\/internalmedicine.45.1498","article-title":"Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.","volume":"45","author":"Yanada","year":"2006","journal-title":"Intern Med"},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1365-2036.2005.02427.x","article-title":"A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.","volume":"21","author":"de Wet","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis.","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"R35-20230928","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2014.136","article-title":"Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.","volume":"49","author":"Park","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/MPH.0b013e318299c6bd","article-title":"Efficacy and safety of micafungin for febrile neutropenia in pediatric patients with hematological malignancies: a multicenter prospective study.","volume":"35","author":"Kobayashi","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1542\/peds.2008-1158","article-title":"A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.","volume":"123","author":"Zaoutis","year":"2009","journal-title":"Pediatrics"},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-3062.2008.00349.x","article-title":"Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.","volume":"11","author":"Kontoyiannis","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jinf.2005.01.006","article-title":"Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections.","volume":"52","author":"Nivoix","year":"2006","journal-title":"J Infect"},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","article-title":"Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.","volume":"53","author":"Denning","year":"2006","journal-title":"J Infect"},{"key":"R41-20230928","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10096-005-0024-8","article-title":"International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.","volume":"24","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R42-20230928","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jinf.2004.05.011","article-title":"Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.","volume":"50","author":"Kartsonis","year":"2005","journal-title":"J Infect"},{"key":"R43-20230928","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.inf.0000145408.51526.0a","article-title":"Caspofungin therapy of neonates with invasive candidiasis.","volume":"23","author":"Odio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R44-20230928","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0609.2004.00254.x","article-title":"Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.","volume":"73","author":"Cesaro","year":"2004","journal-title":"Eur J Haematol"},{"key":"R45-20230928","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1111\/j.1439-0507.2011.02045.x","article-title":"Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.","volume":"54","author":"Cornely","year":"2011","journal-title":"Mycoses"},{"key":"R46-20230928","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/14740338.2011.557062","article-title":"Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.","volume":"10","author":"Cornely","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"R47-20230928","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/INF.0b013e3182127eaf","article-title":"Safety of micafungin in pediatric clinical trials.","volume":"30","author":"Arrieta","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R48-20230928","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/INF.0b013e3181af5a15","article-title":"Safety experience with caspofungin in pediatric patients.","volume":"28","author":"Zaoutis","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R49-20230928","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/ped.12157","article-title":"Micafungin versus fluconazole for prophylaxis against fungal infections in premature infants.","volume":"55","author":"Maede","year":"2013","journal-title":"Pediatr Int"},{"key":"R50-20230928","first-page":"1692","article-title":"[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation].","volume":"50","author":"Sawada","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"R51-20230928","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R56-20230928","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/tropej\/fmr025","article-title":"A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.","volume":"58","author":"Mohamed","year":"2012","journal-title":"J Trop Pediatr"},{"key":"R57-20230928","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2012.09156.x","article-title":"A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children.","volume":"158","author":"Caselli","year":"2012","journal-title":"Br J Haematol"},{"key":"R58-20230928","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","article-title":"Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.","volume":"34","author":"Wang","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R59-20230928","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3760\/cma.j.issn.0366-6999.20132680","article-title":"Caspofungin versus liposomal amphotericin B for treatment of invasive fungal infections or febrile neutropenia.","volume":"127","author":"Zhang","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R60-20230928","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1592\/phco.30.12.1207","article-title":"Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.","volume":"30","author":"Kale-Pradhan","year":"2010","journal-title":"Pharmacotherapy"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201901000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T12:11:58Z","timestamp":1719922318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201901000-00010"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002032","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}